• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Long-term effects of finasteride on prostate tissue composition.

作者信息

Marks L S, Partin A W, Dorey F J, Gormley G J, Epstein J I, Garris J B, Macairan M L, Shery E D, Santos P B, Stoner E, deKernion J B

机构信息

Department of Urology, University of California, Los Angeles School of Medicine, USA.

出版信息

Urology. 1999 Mar;53(3):574-80.

PMID:10096387
Abstract

OBJECTIVES

To determine the long-term effects of finasteride treatment on prostate tissue composition; to relate these effects to clinical outcomes; and to test the hypothesis that finasteride exerts a selective or preferential action on the transition zone.

METHODS

Nineteen men with symptomatic benign prostatic hyperplasia (BPH) who completed a 6-month double-blind trial of finasteride were enrolled in a 24-month open-label extension study of drug responders. Magnetic resonance imaging and prostate biopsy for morphometric analysis were performed together 70 times: at baseline (n = 19), after treatment periods of intermediate duration (6 to 18 months, n = 32), and after long-term drug treatment (24 to 30 months, n = 19). At baseline, prostate volume averaged 51 cc, of which 57% was transition zone.

RESULTS

Decreases in symptom score, dihydrotestosterone and prostate-specific antigen levels, and prostate volume occurred at 6 months (P <0.01), stabilized, and were maintained without further long-term decreases. Prostate epithelium contracted progressively from baseline (19.2% tissue composition; 6.0-cc volume; 3.2 stroma/epithelial ratio) to intermediate (12.5%, 3.3 cc, and 5.6, respectively) to long-term treatment (6.4%, 2.0 cc, and 17.4, respectively, P <0.01 for all). Percent epithelial contraction was similar in the peripheral and transition zones (P = NS). The transition zone remained a relatively constant proportion (53% to 58%) of whole-prostate volume from baseline to long-term observation.

CONCLUSIONS

Long-term finasteride treatment (24 to 30 months) results in a marked involution of the prostate epithelium, which continues to progress for many months after clinical effects stabilize. The effect on the epithelium is similar in the peripheral and transition zones for both morphometric and volumetric changes. Progressive contraction of the prostate epithelium appears to constitute the underlying mechanism for sustained action of finasteride.

摘要

相似文献

1
Long-term effects of finasteride on prostate tissue composition.
Urology. 1999 Mar;53(3):574-80.
2
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.度他雄胺对前列腺外周带和移行带的影响以及移行带指数在预测治疗反应中的价值。
J Urol. 2007 Apr;177(4):1408-13. doi: 10.1016/j.juro.2006.11.095.
3
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.非那雄胺对良性前列腺增生男性急性尿潴留风险及手术治疗需求的影响。非那雄胺长期疗效和安全性研究组。
N Engl J Med. 1998 Feb 26;338(9):557-63. doi: 10.1056/NEJM199802263380901.
4
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
J Urol. 1997 Jun;157(6):2171-8.
5
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.非那雄胺治疗良性前列腺增生症男性6年,急性尿潴留和手术发生率持续下降。
J Urol. 2004 Mar;171(3):1194-8. doi: 10.1097/01.ju.0000112918.74410.94.
6
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.非那雄胺对前列腺特异性抗原水平的长期影响:前列腺癌预防试验的结果
J Urol. 2005 Sep;174(3):877-81. doi: 10.1097/01.ju.0000169255.64518.fb.
7
Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.双重5α-还原酶抑制剂度他雄胺长期治疗有症状的良性前列腺增生男性的疗效和安全性。
Eur Urol. 2004 Oct;46(4):488-94; discussion 495. doi: 10.1016/j.eururo.2004.05.008.
8
[Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
Urol Nefrol (Mosk). 1998 Jul-Aug(4):37-9.
9
A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia.一项评估非那雄胺治疗良性前列腺增生组织效应的前瞻性随机试验。
Prostate Cancer Prostatic Dis. 1999 Dec;2(5/6):277-281. doi: 10.1038/sj.pcan.4500377.
10
Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
Ann Chir Gynaecol. 1999;88(4):299-303.

引用本文的文献

1
Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia.空间转录组学鉴定前列腺增生良性病变中候选基质驱动因素。
JCI Insight. 2024 Jan 23;9(2):e176479. doi: 10.1172/jci.insight.176479.
2
Preoperative predictors of enucleation time during en bloc 'no-touch' holmium laser enucleation of the prostate.整块“无接触”钬激光前列腺剜除术中眼球摘除时间的术前预测因素。
BMC Urol. 2020 Nov 11;20(1):185. doi: 10.1186/s12894-020-00758-4.
3
The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
5-α还原酶抑制剂在良性前列腺增生治疗中的应用。
Asian J Urol. 2018 Jan;5(1):28-32. doi: 10.1016/j.ajur.2017.11.005. Epub 2017 Nov 26.
4
Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia.MRI 前列腺分段和体积测定在良性前列腺增生中的临床价值。
Diagn Interv Radiol. 2014 May-Jun;20(3):229-33. doi: 10.5152/dir.2014.13322.
5
MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes.5α-还原酶抑制剂对前列腺各区体积动态影响的MRI特征分析
Can J Urol. 2013 Dec;20(6):7002-7.
6
Is transforming growth factor-β signaling activated in human hypertrophied prostate treated by 5-alpha reductase inhibitor?5α-还原酶抑制剂治疗的人前列腺增生组织中是否激活转化生长因子-β信号转导?
Dis Markers. 2013;35(6):679-85. doi: 10.1155/2013/783287. Epub 2013 Nov 6.
7
An introduction to acinar pressures in BPH and prostate cancer.良性前列腺增生和前列腺癌中的腺泡压力简介。
Nat Rev Urol. 2013 Jun;10(6):358-66. doi: 10.1038/nrurol.2013.86. Epub 2013 May 14.
8
A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.术前 5α-还原酶抑制剂对良性前列腺增生症手术中出血的影响及作用机制的系统评价。
Asian J Androl. 2011 Nov;13(6):812-8. doi: 10.1038/aja.2011.86. Epub 2011 Sep 5.
9
Finasteride for benign prostatic hyperplasia.非那雄胺用于良性前列腺增生症。
Cochrane Database Syst Rev. 2010 Oct 6;2010(10):CD006015. doi: 10.1002/14651858.CD006015.pub3.
10
The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.雄激素水平对多尺度数学模型中前列腺癌的进化影响。
Biol Direct. 2010 Apr 20;5:24. doi: 10.1186/1745-6150-5-24.